Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03639194 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03639194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
October 24, 2018
Completion date
January 25, 2024
Enrollment
132 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer